CN105982905A - Application of 20 (R)-ginsenoside Rg3 in preparing medicine for preventing and/or treating obesity and medicine - Google Patents

Application of 20 (R)-ginsenoside Rg3 in preparing medicine for preventing and/or treating obesity and medicine Download PDF

Info

Publication number
CN105982905A
CN105982905A CN201510065281.3A CN201510065281A CN105982905A CN 105982905 A CN105982905 A CN 105982905A CN 201510065281 A CN201510065281 A CN 201510065281A CN 105982905 A CN105982905 A CN 105982905A
Authority
CN
China
Prior art keywords
extract
medicine
ginsenoside
obesity
health product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510065281.3A
Other languages
Chinese (zh)
Inventor
富力
惠敏
王凯乾
刘正贤
鲁明明
盖鑫
柳洋
鲁岐
刘国友
王硕
樊宏宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510065281.3A priority Critical patent/CN105982905A/en
Priority to PCT/CN2016/071569 priority patent/WO2016124080A1/en
Publication of CN105982905A publication Critical patent/CN105982905A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)

Abstract

The invention discloses a novel application of 20 (R)-ginsenoside Rg3 in preparing a medicine for preventing and/or treating obesity. Tests prove that the 20 (R)-ginsenoside Rg3 is significant in curative effect on treating the obesity, rapid to take effect and low in toxic and side effects; and the 20 (R)-ginsenoside Rg3, as an obesity-treating medicine, which is safe, efficient, stable and simple in preparation process, is applicable to industrial production and is easy for popularization. The invention provides a novel medicine source for preventing and treating the obesity and complications thereof.

Description

20 (R)-ginsenoside Rg3s in preparation prevention or/and the application in obesity treating medicine and medicine
Technical field
The invention belongs to field of medicaments, relate to a kind of medicine treating obesity or health food, particularly to one Chinese medicine Radix Ginseng extract component in prevention or/and application in obesity treating medicine or health food.
Background technology
Obesity is commonly called as affluenza, and along with the living standard of people constantly improves, obesity is the most increasingly closed Note, can foretell the fat one of the main reasons healthy by becoming 21 century impact.Obesity is due to heredity Jointly act on environmental factors, cause body fat to be piled up too much and (or) abnormal distribution, the result that body weight increases. World Health Organization (WHO) thinks that obesity is the epidemic diseases of most of developed country and developing country.At present, the whole world Having 1,000,000,000 people overweight, China adult is overweight and overweight people nearly 15%, and rough estimate, the whole nation has super severe one extremely at present Few 2～300,000,000 people, obesity patient, at least at 3～4 million people, also has data to be shown to be 70,000,000 people.Fat Not only affecting figure and activity, body fat accumulation can bring the change of a series of physiological function.Obesity is also simultaneously Add the incidence rate of some diseases, such as coronary artery disease, cardiac arrest, arterial hypertension, Peripheral blood Pipe disease, hyperlipemia, diabetes, gout, pulmonary insufficiency, sleep-respiratory all standing, osteoarthritis, gallbladder Capsulitis and lower for the resistance and infect, cholelithiasis, chronic venous stasis ulcer, gastroesophageal reflux, gonadal hormone Imbalance causes dysmenorrhea, hirsutism, infertility and urgent micturition, frequent micturition.Additionally, carcinoma of endometrium, colon cancer, prostatitis Adenocarcinoma and breast carcinoma the most likely increase in the incidence rate of adiposis patient, and after amenorrhea, obesity can increase obese patient uterus Cancer and the danger of breast carcinoma.Obese patient's liver fat is piled up too much, and intrahepatic fat acid synthesis increases, oxidation barrier Hinder, decompose, export minimizing, various forms of fatty acid all can be caused wherein to be mainly triglyceride heap in liver Long-pending.The oxidation product of these fatty acids and fatty acid can destroy hepatocyte biomembrane, thus produces cytotoxicity. Too much triglyceride is deposited in liver, is gathered into lipid droplet, and it is gradually increased, and can make swelling of liver cell；Fat Fat is accumulated in liver for a long time, affects the oxygen supply of liver, blood supply, add own metabolism by long lasting effect, these are equal Inflammatory cell can be caused to invade profit, degeneration necrosis, cause fat hepatitis.Once liver has fibroplasia and pseudolobuli Formed, be formed for fatty liver.The most typically use Body Mass Index (BMI) i.e. body weight/height (m)2Sentence with waistline Fixed fat degree.In China, preferable BMI value is 21kg/m2, BMI value is fat more than 24.BMI The too high main risk factor being type ii diabetes and falling ill.Along with the rising of BMI, the probability of onset diabetes becomes Increase again.The impact of deduction age factor, with the BMI same sex less than 21 compared with others, BMI is more than 35 Women and male's danger of suffering from diabetes raise 93 times and 42 times respectively.Moreover, it is noted that fat The distribution of fat tissue is also an important risk factor of onset diabetes, even if BMI controlled in normal range In, if waistline is more than 102cm, the initiation potential of diabetes also can improve 3.5 times.Especially senile adiposity glycosuria Patient, due to obesity, adipose cell invades profit, and the insulin receptor number on cell membrane reduces, endogenous and external source Property insulin sensitivity reduce, cause blood glucose to raise.Government functionary's investigation to the mean age is 62 years old shows, one The most overweight more than half and type ii diabetes of abdominal obesity person and the too high prevalence of fasting glucose apparently higher than non-overweight and Non-obese person, the rate of rise of triglyceride the most substantially increases.Most of obese patient's body oxygen consumption increase, and the heart is defeated Output increases.The increase of obese patient's blood volume is directly proportional to body weight.The increase of blood volume causes ventricular filling amount Increase, and ventricular filling amount and kinemic increase can cause the change of cardiac structure, cause eccentric hypertrophy. Research shows, the weight of left ventricle and the proportional relation of BMI.The increase of When cardiac output merges peripheral blood vessel resistance When power increases, the generation of hypertension will be caused, and then cause ventricle wall to thicken, produce concentric hypertrophy.At one Finding in the heart disease research of entitled Framingham, the size of body weight and congestive heart failure have direct relation. Additionally, due to the hypertrophy of left ventricle can increase the Probability of coronary heart disease and arrhythmia etc..Obese women post menopausal Increasing with the age, intra abdominal fat content increases, and the risk factor of cardiovascular diseases increases.Therefore, obesity also with hat Cardiopathia is relevant with arrhythmia." the athero impact of thoracic wall and abdominal part that obesity can also cause sleep one disordered breathing Thorax and every the motion of flesh.General is fat many without obvious clinical manifestation, and can draw for minority extremely overweight people Play the obstacle of ventilatory function, arterial oxygen saturation thus can be made to decline and carbon dioxide saturation raises, and breathe Suspending, final there is lasting hypoxia and hypercapnia.It is referred to as obesity-related hypoventilation clinically (obesity hypoventilation) syndrome, has another name called piekwiekian syndrome.Additionally, obesity also can cause one Problem in terms of the psychology of series and social adjustment, the degradation as felt oneself inferior, under forgetful, mental retardation, Social adaptability.
Treatment currently for obesity mainly has dietary behavior therapy, exercise therapy, Drug therapy and surgery hands Art.For most of obese patients, reduce Heat energy absorption and increase sports are far from being enough, usually After being off fat-reducing, body weight rises rapidly, has been even more than the body weight before fat-reducing. and (conventional having is vertical to select surgical operation Straight colligation gastroplasty and gastric bypass) think that again risk is too big, it is not easily accepted by.And drug application treatment in early days can be pre- The appearance of anti-complication, strengthens the confidence of patient.Effectiveness and the safety of life-time service in view of current appetrol Property not yet attain ideal, therefore should select therapeutic scheme according to different situations individuation, must adhere to controlling drink simultaneously Food uses appetrol on the basis of doing more physical exercises.The appetrol having developed now listing mainly have two categories below: one is appetite Inhibitor, this kind of medicine mainly makes people produce anorexia to reduce food by the hypothalamic feeding center of regulation The absorption of thing, such as fenfluramine (fenfluramine) and sibutramine (sibutramine) etc..Owing to food contains a lot The nutrition that other bodies are required, long-term fasting will produce the most serious consequence to body, adds that fragrant fluorine draws Bright and Isomeride is to valvular damage, and this medicine was prohibitted the use of by FDA in 1997 at present；West Cloth Qu Ming is also because xerostomia, headache, cardiopalmus, and blood pressure rises high untoward reaction, and its application is very limited.Two It is lipid absorption inhibitor, such as orlistat (Orlistat), makes lipid at intestinal by the lipase of suppression intestinal Absorbing and reduce, life-time service can cause the shortage of the materials such as internal fatsoluble vitamin, and owing to there being cause colon cancer danger Danger, United States Consumer's organizational requirements orlistat withdraws from market.
Rare medicinal herbs in Radix Ginseng Chinese medicine, ginsenoside, as the principle active component of Radix Ginseng, is widely studied and uses, Wherein the most noticeable with 20 (R)-ginsenoside Rg3s, it is as the principle active component of Radix Ginseng, and safety is good Good, have been made into antitumor oral formulations and be applied to clinic, furtherd investigate as injection.
The present inventor uses the separating and purifying technology of advanced person to extract having of its treatment obesity from ginseng crude drug Effect composition 20 (R)-ginsenoside Rg3, can be obesity patient's medicine of providing a kind of high-efficiency low-toxicity.
Summary of the invention
The primary and foremost purpose of the present invention be for existing bariatrician treatment present in technical problem, it is provided that 20 (R)- Ginsenoside Rg3's prevention is or/and treat the new opplication of obesity, and provides 20 (R)-ginsenoside Rg3s to control Treat performance and effect of obesity, i.e. in medicine or the health food treating, nurse one's health and alleviating obesity disease New opplication.
For achieving the above object, one aspect of the present invention provides a kind of 20 (R)-ginsenoside Rg3s to be used for preventing in preparation Or/and the application in obesity treating medicine or health product.
During screening has prevention or/and treat the active skull cap components of obesity effect, inventor finder In the chemical composition of ginseng, 20 (R)-ginsenoside Rg3s have the effect of strong suppression obesity.
Wherein, described medicine is made up of 20 (R)-ginsenoside Rg3s and pharmaceutically acceptable carrier.
Wherein, 20 described (R)-ginsenoside Rg3 content >=1%, it is preferably >=30%, more preferably >=60%, Further it is preferably >=80%, is more further preferably >=98%.
Particularly, 20 described (R)-ginsenoside Rg3 content are 1%～98%；It is preferably 30～80%, enters one Step is preferably 60%.
Particularly, pharmaceutically acceptable carrier is generally used for this purpose and as medicament by sanitarian's accreditation Non-active ingredient.Compilation about pharmaceutically acceptable carrier can be in " handbook of pharmaceutical excipients " (Handbook of Pharmaceutical excipients, second edition are compiled by A.Wade and P.J.Weller Volume；American Pharmaceutical Association publishes, Washington and The Pharmaceutical Press, London, 1994) etc. reference book finds.
Especially, described carrier includes excipient, such as starch, water etc.；Lubricant, such as magnesium stearate etc.； Disintegrating agent, such as microcrystalline Cellulose etc.；Filler, such as lactose etc.；Binding agent, such as pregelatinized Starch, dextrin etc.； Sweeting agent；Antioxidant；Preservative, correctives, spice etc.；
Wherein, described medicine with tablet, capsule, pill, powder, granule, syrup, solution, Emulsion, injection, spray, aerosol, gel, cream, cataplasma, rubber plaster unguentum or emplastrum shape Formula exists.
Particularly, 20 described (R)-ginsenoside Rg3 content >=1%, preferably >=30%, more preferably >=60%, further it is preferably >=80%, is more further preferably >=98%.
Another aspect of the present invention provides the one prevention containing 20 (R)-ginsenoside Rg3s or/and treat obesity Medicine or health product.
Wherein, 20 described (R)-ginsenoside Rg3 content >=1%, it is preferably >=30%, more preferably >=60%, Further it is preferably >=80%, is more further preferably >=98%.
Particularly, 20 described (R)-ginsenoside Rg3 content >=1%, preferably 1%～98%；Be preferably 30～ 80%, the most preferably 60%.
Particularly, the weight of described 20 (R)-ginsenoside Rg3s with the ratio of the gross weight of described medicine or health product is 0.01～10:100, preferably 0.1～10:100, more preferably 1～10:100.
Particularly, described medicine or health product also include Radix Et Rhizoma Rhei extract, Huai Goat, Rhizoma Polygoni Cuspidati extract, Rhizoma Atractylodis extract, Rhizoma Alismatis extract, CAOJUEMING extract, Folium Sennae extract, Semen Coicis extract, Fructus Crataegi Extract, Fructus Ligustri Lucidi extract, Fructus Corni extract, Fructus Lycii extract, Flos Chrysanthemi extract soybean protein powder, One or more in soybean phospholipid.
Described medicine can use method well known in the art to make various dosage form, as tablet, capsule, pill, Powder, granule, syrup, solution, Emulsion, injection, spray, aerosol, gel, cream, Cataplasma, rubber plaster unguentum or emplastrum etc..
Present invention also offers a kind of method treating obesity, give therapeutically effective amount including to experimenter The pharmaceutical composition of 20 (R)-ginsenoside Rg3s, its therapeutically effective amount is 0.06～12mg/kg.d, is preferably 1～6mg/kg.d, more preferably 1.5～3mg/kg.d.
Unless otherwise indicated, term used herein " therapeutically effective amount " is the use needing to produce the medicine of useful effect Amount；" therapeutically effective amount " can adjust and change, and is finally determined by medical worker, the factor bag that it is considered Include ordinary circumstance and the character of treated disease such as route of administration and the character of preparation, the body weight of receiver, age And the order of severity.
Compared with prior art, the present invention has a following obvious advantage:
1, known compound 20 (R)-ginsenoside Rg3 has been excavated new medical value by the present invention, uses it for delaying Solve, treat obesity, and can be prepared as preventing or/and treat medicine or the health food of obesity, thus A new field has been opened up in application for ginseng crude drug.
2, campaign research proof 20 (the R)-ginsenoside Rg3 of the present invention has significantly prevention, treatment fertilizer Effect of fat disease.
3,20 (R)-ginsenoside Rg3 pharmacological actions of the present invention are strong, for preventing, nursing one's health and treat obesity Effect is notable, and instant effect, toxic and side effects are little, safety good, it is possible to long-term taking, have good prospect in medicine.
4, the products material abundance of the present invention, inexpensive, Clinical practice safety, preparation technology is simple, can be made into Various dosage forms, and dosing is little, easy to use, it is thus susceptible to promote.
5, the present invention both can use 20 (R)-ginsenoside Rg3 active component preparations of single component to be used for preventing and controlling Treat the medicine of obesity, 20 (R)-ginsenoside Rg3s can be used again (such as to carry with Radix Et Rhizoma Rhei with other active component Take thing, Huai Goat, Rhizoma Polygoni Cuspidati extract, Rhizoma Atractylodis extract, Rhizoma Alismatis extract, CAOJUEMING extract, Senna fruit Leaf extract, Semen Coicis extract, Fructus Crataegi extract, Fructus Ligustri Lucidi extract, Fructus Corni extract, Fructus Lycii One or more in extract, Flos Chrysanthemi extract soybean protein powder, soybean phospholipid) common prescription, preparation treatment The compound medicine of obesity.
Detailed description of the invention
The beneficial effect of formula of the present invention is further described, these embodiments below by detailed description of the invention It is only exemplary, the scope of the present invention is not constituted any restriction.It will be understood by those skilled in the art that The details of technical solution of the present invention and form can be carried out under without departing from the formula thinking of the present invention, purposes scope Amendment or replacement, but these amendments and replacement each fall within protection scope of the present invention.
Embodiment 1 Rg3 tablet
Rg3 tablet is prepared according to following proportioning:
After ginsenoside Rg3 and starch mix homogeneously, make granule, add Pulvis Talci and magnesium stearate mixing is equal 10000 it are pressed into after even.
Embodiment 2 Rg3 granule
Rg3 granule is prepared according to following proportioning:
Ginsenoside Rg3's (content 63%) 200g
Microcrystalline Cellulose 1000g
After ginsenoside Rg3 and microcrystalline Cellulose mix homogeneously, make granule pack, make 10000 bags.
Embodiment 3 Rg3 capsule
Rg3 capsule is prepared according to following proportioning:
Ginsenoside Rg3's (content 98%) 10g
Starch 1000g
By encapsulated after ginsenoside Rg3 and starch mix homogeneously, make 10000.
Embodiment 4 Rg3 tablet
Rg3 tablet is prepared according to following proportioning:
To pelletize after ginsenoside Rg3, Radix Et Rhizoma Rhei extract, Fructus Crataegi extract and starch mix homogeneously, add It is pressed into 10000 after Pulvis Talci and magnesium stearate mixing.
Embodiment 5 Rg3 capsule
Rg3 capsule is prepared according to following proportioning:
Ginsenoside Rg3's (content 63%) 30g
Rhizoma Atractylodis Macrocephalae extract 30g
Starch 1000g
By encapsulated after ginsenoside Rg3, Rhizoma Atractylodis Macrocephalae extract and starch mix homogeneously, make 10000.
Embodiment 6 Rg3 granule
Rg3 granule is prepared according to following proportioning:
Ginsenoside Rg3, Semen Coicis extract, Fructus Ligustri Lucidi extract, soybean phospholipid and soybean protein powder are mixed Pack after uniformly making granule, make 10000 bags.
Test example 1 20 (R)-ginsenoside Rg3 treats the experimentation of Obesity of Rats disease
1 experiment material
1.1 medicines and reagent
Ginsenoside Rg3 (content ＞ 98%), Dalian Fu Sheng natural drug development corporation, Ltd. produces, lot number: 20120303；With Nat'l Pharmaceutical & Biological Products Control Institute provide ginsenoside Rg3's standard control and carry out HPLC Demarcating, content is 98.2%；
Positive control drug:
Orlistat capsule, Chongqing Watson Pharmaceutical Co., Ltd, lot number: 2011-1002；
Pentobarbital sodium, Solution on Chemical Reagents in Shanghai purchasing and supply station subpackage factory import subpackage, lot number: 120112；Used time It is made into 0.4% aqueous solution.
1.2 animal
Wistar rat, body weight 200 ± 20g, male and female dual-purpose, purchased from Dalian Medical Univ's Experimental Animal Center, matter The amount quality certification number: SCXK (13) 2002-0002.
1.3 animal feed
Normal diet is purchased from Dalian Medical Univ's Experimental Animal Center, and the proportioning of normal diet is as follows: flour 19% is beautiful Rice and flour 23% Sorghum vulgare Pers. powder 6% wheat bran 10% soybean meal 15% vegetable oil 2% cod-liver oil 1% fish flour 10% bone meal 1% beer yeast 1% Sal 1% starch 6.6% glycine 3.4% methionine 0.5% calcium carbonate 0.5%.
High fat high salt feedstuff, its proportioning is as follows: normal diet 100g, lard stearin 10g, whole milk powder 10g, chicken 1, egg, cod-liver oil 10, fresh Semen Glycines Germinatus 250g, Sal 2.5%.Fresh Semen Glycines Germinatus is dried, smash by Ratio, with normal diet mixing for standby use, weighs mixed fodder every day in proportion and adds egg, milk powder, cod-liver oil, food Salt adds water, and to pinch growth strip standby in mixing.
1.4 instrument
TP 100 electronic table Cheng Xiangyi balance equipment factory；
FA 1004 organizes balance Shanghai balance equipment factory；
GF mono-DSOO semi-automatic biochemical analyzer Shandong Gaomi Caihong Analytical Instrument Co., Ltd.；
101 1 ZA type digital display electricity air dry oven PVG Rong Feng scientific instrument company limiteies.
2 experimental techniques
2.1 packets and administration
By rat weight and be randomly divided into 6 groups, often group 10, respectively blank group, model control group, sun Property drug control group, ginsenoside Rg3's high, medium and low dosage group.Blank group after experiment starts by 0.lml/10g Gavage gives pure water；Model control group gives same volume pure water by 0.lml/10g gavage；Positive drug control group Gavage gives orlistat 10mg/kg；The high, medium and low dosage component of ginsenoside Rg3 does not press 6mg/kg, 3mg/ Kg, 1.5mg/kg gavage gives ginsenoside Rg3, once a day.
2.2 modeling method
In addition to blank group gives normal diet, all make high fat high salt feedstuff by oneself, ingest, drink for remaining each group Water is unrestricted, experiment totally 6 weeks.
2.3 observation index
(1) ordinary circumstance；Food ration, amount of drinking water, active situation, feces etc.；
(2) body weight (g), body length (cm), Lee index=(W/H2) (wherein, W is rat body weight；H is big Mus body length), abdominal circumference (cm)；
(3) wet heart weight (g), liver wet weights (g).
2.4 observational technique
Measure food ration, amount of drinking water every day, observe the general state of Mus.Fixing with electronic scale weighing rat body weekly Weight (w), with tape along rat femur upper limb around rat abdomen, records rat abdominal circumference；Fasting at 6th weekend After 12h, with pentobarbital sodium 0.lml/10g intraperitoneal injection of anesthesia, it is strapped on self-control plank, surveys Mus nose with tape To the length of anus, record body length (H)；Then open abdominal cavity, dial from ventral aorta, carry out ventral aorta and adopt Blood, with 2500 revs/min of centrifuge, 10 minutes centrifugation serum, puts in shell pipe with pipettor extraction serum, It is placed in 20 DEG C of refrigerators and saves backup；Then pluck rat heart, liver, and claim weight in wet base with tissue balance.
3 result of the tests
The general state of 3.1 test rats is observed and diet drinking-water change
Rat mental status no abnormality seen during experiment, model control group gait is slack, fluffy by hair, does not like activity, Sometimes loose stool, remaining each administration group rat is the most active, has no depilation, matt, sialorrhea, and pellet morphology changes Deng abnormal response.In experimentation, each administration group food ration, amount of drinking water and model control group do not have difference, without statistics Learn meaning (P > 0.05), but high lipid food respectively organizes food ration, amount of drinking water is slightly more than chow diet group.
3.2 ginsenoside Rg3s are on rat body weight, body length, the impact of Lee index
Table 1 shows 20 (the R)-ginsenoside Rg3s impact on the upgrowth situation of rat, rat body weight, body length, Lee Assessment of indices the results are shown in Table 1.
Table 1 Growth in Rats changed condition
Note: compare * P < 0.05**P < 0.01***P < 0.00 with model group, with blank group △ P < 0.01 △ △ P < 0.001.
From table 1, model group rats body weight and normal rats weight ratio more variant (P < 0.01)；Model group is big Mus Lee index and normal rats Lee index more variant (P < 0.001), prompting obesity rat model success； Ginsenoside Rg3's high dose group rat body weight and model group rats weight ratio more variant (P < 0.001)；High dose group Rat Lee index and model group rats Lee index more variant (P < 0.001)；Dosage in ginsenoside Rg3 Group rat Lee index and model group rats Lee index more variant (P < 0.01)；Ginsenoside Rg3's low dosage Group rat Lee index and model group rats Lee index more variant (P < 0.05), point out 20 (R)-ginsenosides The high, medium and low dosage of Rg3 can significantly reduce rat body weight, reduce Lee index, has antiobesity action, due to Each group body length does not has difference, prompting 20 (R)-ginsenoside Rg3s not to affect the growth of animal.
3.3 ginsenoside Rg3s impact on viscera in rats weight in wet base
20 (R)-ginsenoside Rg3s are shown in Table 2 to the result of the test that affects of viscera in rats weight in wet base
Table 2 viscera in rats weight in wet base changes
Note: compare * P < 0.05**P < 0.01 with model group and compare △ P < 0.05 with blank group
From table 2, model group rats heart, liver and normal group more variant (P < 0.05), high fat is pointed out to raise Material increases obese rat internal organs risk；Ginsenoside Rg3's high dose group rat liver and model group rats liver Relatively variant (P < 0.01), prompting 20 (R)-ginsenoside Rg3s can reduce liver wet weights, improves interior fat Metabolism disorder, has effect of fat-reducing, can be used for treating obesity.

Claims (10)

1.20 (R)-ginsenoside Rg3s in preparation for prevention or/and application in obesity treating medicine or health product.
Application the most according to claim 1, is characterized in that described medicine is by 20 (R)-ginsenoside Rg3s and pharmaceutically Acceptable carrier forms.
Application the most according to claim 1 and 2, it is characterized in that described medicine with tablet, capsule, pill, Powder, granule, syrup, solution, Emulsion, injection, spray, aerosol, gel, cream, Cataplasma, rubber plaster unguentum or emplastrum form exist.
Application the most according to claim 1 and 2, is characterized in that content >=1% of 20 described (R)-ginsenoside Rg3s.
Application the most according to claim 4, is characterized in that the content of 20 described (R)-ginsenoside Rg3s is 1%～98%.
6. prevention is or/and the medicine for the treatment of obesity or health product, it is characterized in that containing 20 (R)-ginsenoside Rg3s.
Medicine the most according to claim 6 or health product, is characterized in that the weight of described 20 (R)-ginsenoside Rg3s It is 0.01～10:100 with the ratio of the gross weight of described medicine or health product.
Medicine the most according to claim 6 or health product, is characterized in that containing of 20 described (R)-ginsenoside Rg3s Amount is for >=1%.
Medicine the most according to claim 8 or health product, is characterized in that containing of 20 described (R)-ginsenoside Rg3s Amount is 1%～98%.
Medicine the most according to claim 6 or health product, is characterized in that also including that Radix Et Rhizoma Rhei extract, the Flos Sophorae Immaturus carry Take thing, Rhizoma Polygoni Cuspidati extract, Rhizoma Atractylodis extract, Rhizoma Alismatis extract, CAOJUEMING extract, Folium Sennae extract, the heart of a lotus seed Semen Coicis extract, Fructus Crataegi extract, Fructus Ligustri Lucidi extract, Fructus Corni extract, Fructus Lycii extract, Flos Chrysanthemi One or more in extract, soybean protein powder, soybean phospholipid.
CN201510065281.3A 2015-02-06 2015-02-06 Application of 20 (R)-ginsenoside Rg3 in preparing medicine for preventing and/or treating obesity and medicine Pending CN105982905A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510065281.3A CN105982905A (en) 2015-02-06 2015-02-06 Application of 20 (R)-ginsenoside Rg3 in preparing medicine for preventing and/or treating obesity and medicine
PCT/CN2016/071569 WO2016124080A1 (en) 2015-02-06 2016-01-21 Use of 20(r)-ginsenoside rg3 in preparation of drug for preventing or/and treating obesity and drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510065281.3A CN105982905A (en) 2015-02-06 2015-02-06 Application of 20 (R)-ginsenoside Rg3 in preparing medicine for preventing and/or treating obesity and medicine

Publications (1)

Publication Number Publication Date
CN105982905A true CN105982905A (en) 2016-10-05

Family

ID=56563434

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510065281.3A Pending CN105982905A (en) 2015-02-06 2015-02-06 Application of 20 (R)-ginsenoside Rg3 in preparing medicine for preventing and/or treating obesity and medicine

Country Status (2)

Country Link
CN (1) CN105982905A (en)
WO (1) WO2016124080A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108704060A (en) * 2018-09-03 2018-10-26 杭州市红十字会医院 A kind of defaecation disappears the Chinese medicine composition and preparation method thereof of fat
CN111840351A (en) * 2019-04-29 2020-10-30 成都中医药大学 Medicine for treating chronic atrophic gastritis and preparation method thereof
CN112023000A (en) * 2020-09-25 2020-12-04 陕西中医药大学 Weight-reducing pill

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102599303A (en) * 2011-01-24 2012-07-25 吉林农业大学 Ginseng leaf tea subjected to micronization and fermentation and preparation method thereof
CN103845349A (en) * 2012-11-30 2014-06-11 富力 Application of 20(R)-ginsenoside Rg3 in preparation of medicines for treating leucoderma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100618171B1 (en) * 2003-04-30 2006-08-29 김재백 Fermented red ginseng containing ginseng saponin degradate and its manufacturing method
KR100877604B1 (en) * 2007-05-09 2009-01-09 주식회사 진생사이언스 Composition comprising an extract of processed ginseng for preventing and treating obesity
CN101530389B (en) * 2008-03-11 2012-02-15 沈阳市万嘉生物技术研究所 Ginsenoside Rg 3 and phospholipid complex and preparing method thereof
KR101457621B1 (en) * 2012-01-26 2014-11-10 주식회사 아리바이오 Methods for Preparing Rg3 or Rg2 Group Ginsenosides and Compositions for Preventing or Treating Metabolic Diseases
CN103845348B (en) * 2012-11-30 2016-07-13 富力 20 (R)-ginsenoside Rg3s application in preparation dysmenorrhea medicine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102599303A (en) * 2011-01-24 2012-07-25 吉林农业大学 Ginseng leaf tea subjected to micronization and fermentation and preparation method thereof
CN103845349A (en) * 2012-11-30 2014-06-11 富力 Application of 20(R)-ginsenoside Rg3 in preparation of medicines for treating leucoderma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
刘新旗 等: "大豆蛋白的营养保健功能研究现状", 《北京工商大学学报（自然科学版）》 *
李松伟 等: "中医药治疗单纯性肥胖症研究近况", 《河南中医学院学报》 *
薛莉 等: "借助联盟力量 发挥优势强项——做新做大做高做强大豆磷脂产业", 《大豆科技》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108704060A (en) * 2018-09-03 2018-10-26 杭州市红十字会医院 A kind of defaecation disappears the Chinese medicine composition and preparation method thereof of fat
CN111840351A (en) * 2019-04-29 2020-10-30 成都中医药大学 Medicine for treating chronic atrophic gastritis and preparation method thereof
CN112023000A (en) * 2020-09-25 2020-12-04 陕西中医药大学 Weight-reducing pill

Also Published As

Publication number Publication date
WO2016124080A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
CN109700939B (en) Application of dendrobium officinale leaf, rhizoma polygonati and radish seed in preparation of medicine for treating hypertension
CN105982905A (en) Application of 20 (R)-ginsenoside Rg3 in preparing medicine for preventing and/or treating obesity and medicine
CN106177053A (en) A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae
CN104208425B (en) A kind of Chinese medicine preparation for being used to nurse one&#39;s health critical hypertension
CN112546167A (en) Traditional Chinese medicine composition with spleen invigorating and dampness removing functions and preparation method and application thereof
CN106173605A (en) A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Herba Dendrobii
CN102008083A (en) Health food for alleviating physical fatigue and removing chloasma
CN109453267A (en) Sobering-up composition and the preparation method and application thereof
CN102872368B (en) Chinese medicine acupoint application preparation for purging fire for removing toxin
CN104432057B (en) A kind of health food with endocrine regulation function and preparation method thereof
CN109316565B (en) Blood fat reducing composition and preparation method and application thereof
CN106923335A (en) A kind of function composition of sport nutrition and application
CN105749104A (en) Traditional Chinese medicine preparation capable of developing intelligence and preparation method thereof
CN103417764A (en) Health care product containing L-carnitine
CN104644660A (en) Application of 20(R)-ginsenoside Rg3 in preparation of medicament for relieving or/and treating fatty liver
CN105079391A (en) Effervescent tablets for preventing oral ulcer and preparation method therefor
CN101279086A (en) Chinese medicine for curing gastroptosis
CN111000949A (en) Composition for improving subcutaneous fat type obesity and preparation method thereof
CN108478701A (en) A kind of lozenge of strengthen immunity
CN108967757A (en) A kind of thickened red jujube ginger pulp production technology
CN101164595A (en) Traditional Chinese medicine for curing anorexia
CN104042772B (en) A kind of Chinese medicine composition and preparation method for strengthening immunologic function
CN104815034B (en) A kind of pharmaceutical composition for treating gastrointestinal discomfort caused by antibiotic and its preparation method and application
WO2014134832A1 (en) Composition and preparation method thereof
CN105031354A (en) Unio margarita capsule used for curing gastroduodenal ulcer and preparation method and application of Unio margarita capsule

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161005

WD01 Invention patent application deemed withdrawn after publication